Sanofi India Ltd. share price target

Sanofi's (SANL) 3QCY17 revenue increased ~7% YoY (+11% QoQ) to INR6.7b (~3.4% miss). EBITDA rose 27% YoY to INR1.8b (+21% beat), as margins expanded ~440bp YoY (+830bp QoQ) to 27.5%. Consequently, PAT increased sharply by 44% YoY to INR1.2b (31% beat). High-single-digit revenue growth, coupled with strong margin: According to AIOCD, secondary sales growth for SANL stood at ~6% YoY, higher than industry, which saw flattish growth of 1%. The company's key therapeutic areas posted strong growth during the quarter: Anti-Diabetic portfolio grew...

For 2QCY2017, Sanofi India posted results which were below expectations on all fronts. The sales came in at `556cr v/s. `520cr expected, registering a yoy de-growth of 3.8%. On the operating front, the EBITDA margin came in at 12.7% (17.6% expected) v/s. 18.6% in 2QCY2016. Despite better GPM (Gross Profit Margin), which came in at 55.5% v..

Sanofi India Ltd Q2CY17 results comment Revenue rose by 8.41% to Rs. 555.8 Cr in Q2CY17 when compared to the previous quarter.

For 1QCY2017, Sanofi India posted results which were below expectations on all fronts. The sales came in at `513cr v/s. `550cr expected, registering a yoy de-growth of 1.1%. On the operating front, the EBITDA margin came in at 12.0% (17.6% expected) v/s. 17.7% in 1QCY2016. Despite better GPM (Gross Profit Margin), which came in at 54.2% v..

For 4QCY2016, Sanofi India posted results which were below expectations on the sales front. The sales came in at Rs552cr v/s. Rs570cr expected, posting a yoy growth of 5.6%. On the operating front, the EBITDA margin came in at 12.2% (12.3% expected) v/s. 12.7% in 4QCY2015. This came in-spite of GPM (Gross Profit Margin), which came in at ..

Sanofi India posted results and are below expectations on all fronts. The sales came in at Rs583cr vs. Rs600cr expected, posting a yoy growth of 5.4%. According to AIOCD, secondary sales, growth for Sanofi India was double digit. According to AIOCD, regulatory actions will have negative one-time impact of ~2% on sales of the company. We e..

Sanofi India (Sanofi)'s 1QCY2016 results have come in lower than our expectation; the company posted a 10.1% yoy growth in revenue to Rs506cr V/s an expected Rs593cr. On the operating front, the gross margin came in at 52.1%, almost in line with our expectation, and V/s 47.8% in the corresponding period of last year. The OPM came in at 18..

Double-digit sales growth for third consecutive quarter: Sanofi reported a double-digit growth of 11.4% YoY for the third consecutive quarter since 2QCY15, aided to some extent by higher other operating income of INR637m,...

Sanofi India Ltd. (Sanofi) is a 60.4% subsidiary of Hoechst, Germany (subsidiary of Sanofi SA). Sanofi India Ltd (Sanofi India) is an active pharmaceutical ingredient (API) and formulations...

Sanofi's total revenues increased by 8.7 % YoY to Rs 5.5 bn in Q2CY15 lower than our estimates of Rs 5.8 bn. Operating margins were a major surprise as it moved up from 19.4 % to 22.1% (higher than our estimate of 19.1%). Savings in overheads and employee expenses were the key margin contributors. Net Profit grew by 11.7% YoY to Rs 642 mn as against our estimates of Rs 420 mn.